Relapsing remitting multiple sclerosis

disorder

SNOMED 426373005CUI C0751967

Overview

Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Treatments & Interventions

Glatiramer acetate

substance

Glatiramer

substance

Fingolimod

substance

Fingolimod hydrochloride

substance

Teriflunomide

substance

Siponimod

substance

Ozanimod

substance

Ozanimod hydrochloride

substance

Ponesimod

substance

Diroximel fumarate

substance

Ublituximab

substance

Clinical Trials

Total Trials

Recruiting

With Results

Recent Trials

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

NCT07426991Recruiting837 enrolled

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

NCT05296161Phase 4Recruiting296 enrolled

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

NCT06733922Phase 4Recruiting224 enrolled

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

NCT07225361Phase 4Recruiting40 enrolled

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

NCT04480853Phase 4Recruiting30 enrolled

View all 59 trials on ClinicalTrials.gov

Related Conditions

Multiple sclerosis(parent)

Quick Facts

SNOMED CT: 426373005
UMLS CUI: C0751967
Fully Specified Name: Relapsing remitting multiple sclerosis (disorder)
Specialists: 0
Diagnostic Biomarkers: 0
Known Treatments: 11
Clinical Trials: 59

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.